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Background: Increasing numbers of women ≥40 years are accessing assisted reproductive 
technology (ART) due to age-related infertility. There is limited population-based evidence 
about the impact on the cumulative live birth rate (CLBR) of women aged ≥40 years using 
their own oocytes, compared to women of a similar age, using donor oocytes. 
Aims: Compare the CLBR for women ≥40 years undergoing ART using autologous oocytes and 
women of similar age using donor oocytes. 
Materials and Methods:  This population-based retrospective cohort study used data from 
all women aged ≥40 years undergoing ART with donated (n=987) or autologous oocytes (n=19 
170) in Victoria, Australia between 2009 and 2016. A discrete-time survival model was used 
to evaluate the CLBR following ART with donor or autologous oocytes. The odds ratio, 
adjusted for woman’s age; male age; parity; cause of infertility; and the associated 95% 
confidence intervals (CI), were calculated. The numbers needed-to-be-exposed (NNEs) were 
calculated from the adjusted odds ratio (AOR) and the CLBR in the autologous group. 
Results: The CLBR ranged from 28.6% to 42.5% in the donor group and from 1.4% to 12.5% in 
the autologous group. The discrete-time survival analysis with 95% CI demonstrated 
significant AOR on CLBR across all ages (range AOR: 2.56, 95% CI: 1.62–4.01 to AOR: 15.40, 
95% CI: 9.10–26.04).  
Conclusions: Women aged ≥40 years, using donor oocytes had a significantly higher CLBR 
than women using autologous oocytes. The findings can be used when counselling women 





In recent years, there has been a shift towards later childbearing with the birth rates for 
women ≥40 years at 12.9 births per 1,000 women in 2017, compared to 4.4 births in 19801.  
Reasons cited for this trend include improved access to reliable contraception, women’s 
greater participation in education, developing a career, and the erroneous belief that ART can 
extend the reproductive lifespan2-4.  The lack of a partner willing to commit to parenthood 
has also been cited as a reason for delayed childbearing5. Also, an increasing number of 
divorces and second marriages have contributed to more women in their forties desiring 
children6. Simultaneously, there has been an increase in the use of ART treatments by women 
≥40 years. In Australia and New Zealand, almost a quarter (23.4%) of all ART treatment cycles 
in 2017 were undertaken by women aged ≥40 years compared to 16.1% in 20067. 
Older women contemplating ART face the reproductive dilemma of choosing between using 
their own (autologous) or donor oocytes. Couples’ motivations for using autologous oocytes 
include a strong desire to have a biologically related child8. However, in women ≥40 years, 
the risk of aneuploidy in oocytes may exceed 60%, thereby significantly contributing to low 
embryo implantation rates and low chances of a live birth9. To reduce the risk of aneuploidy 
and increase the likelihood of a live birth, women can use oocytes donated by a younger 
woman, ideally less than 35 years10. In Australia and New Zealand where commercial donation 
(donation with monetary compensation other than “out of pocket” expenses) is prohibited, 
there is a shortage of donor gametes and 36% of oocyte donors are ≥35 years7.  Due to the 
shortage of women who are willing to donate oocytes to someone who is not known to them, 




Whether using autologous or donor oocytes, the chance of having a baby is of fundamental 
interest to people who use ART. However, studies in the United Kingdom, United States and 
Australia show that the quality of information on ART clinic websites, about the chance of 
having a baby as a result of ART, is poor12,13. There are several different ways of presenting 
ART success rates with different authorities arguing for different approaches14-16. Malizia and 
colleagues contend that ART success rates presented as outcome per cycle or embryo transfer 
have limited value because they do not account for the additional chance offered by frozen 
embryo transfers resulting from a stimulated cycle17. The CLBR is advocated as a more useful 
way of presenting the chance of success for both patients and clinicians because it includes 
the added opportunity offered by frozen embryos and provides an overall estimate of the 
possibility of having a baby following one stimulated cycle18.  
The purpose of this population-based cohort study is to quantify the effect of using 
autologous or donated oocytes on the CLBR among women aged ≥40 years. The findings can 
be used when counselling women over 40 contemplating ART to help them and their partners 
make informed decisions about whether to use their own or donor oocytes. 
Materials and Methods 
Data 
The data used in this study were collected from all ART providers in Victoria, Australia.  The 
Victorian Assisted Reproductive Treatment Authority (VARTA) database includes information 
on the ART procedure (including the number of oocytes collected, donated and received; 
method of fertilisation; and whether fresh or thawed embryos were transferred), and the 
outcomes of ART procedures (including birth status, gestational age, birth weight and 
congenital anomalies). Data are collected annually from all ART clinics in Victoria. 
 
 
This study used data from all women aged ≥40 years who had ART treatment between 1 July 
2009 and 30 June 2016 of whom 987 had used donated oocytes, and 19,170 had used their 
own oocytes in 1,983 and 26,638 cycles respectively. Demographic characteristics, treatment 
types and outcomes were recorded for each completed cycle (fresh and associated thaw 
cycles) until a live birth was achieved or until 30th June 2016. 
Study factors 
The women's ages were calculated at the time of the first simulated cycle and categorised 
into eight groups: 40, 41, 42, 43, 44, 45, and ≥46 years.  Male age was grouped as: <30, 30-
34, 35-39, 40-44 and ≥45 years. Previous pregnancy of ≥20 weeks gestation was grouped as 
yes, no and not stated. Fertilisation procedure was either IVF or ICSI. Stage of embryo 
development was grouped into cleavage or blastocyst stage. The numbers of embryos 
transferred were grouped as one, two, three or more embryos. 
Main outcome measure 
The primary outcome was the cumulative live birth rate (CLBR), defined as at least one live 
birth per woman, following a stimulated cycle or oocyte donation and associated thaw cycles. 
A live birth was defined as a baby showing signs of life with gestational age ≥20 weeks or 
birthweight ≥400 grams. Multiple births were counted as one live birth. The observed CLBR 
was calculated over multiple transfers using the conservative assumption that women who 
did not return for treatment did not have a pregnancy resulting in a live birth.  
Statistical analysis 
Descriptive statistics were used for data on women’s age, male partner age, history of 
previous pregnancy of ≥20 weeks gestation, fertilisation procedure, stage of embryo 
development and the number of embryos transferred. CLBR for each age group and cycle 
 
 
numbers were calculated for both autologous and donor oocyte groups. A discrete-time 
survival model was used to evaluate the prognostic significance of ART treatment for the CLBR 
across age groups. The odds ratio, adjusted for the woman’s age; male age; parity 
(nulliparous/parous); and cause of infertility (male only, female only, or unexplained); and its 
associated 95% CI were computed. Descriptive statistical analysis was performed using SPSS 
25 (Armonk, NY, USA: IBM Corp.) and R version 3.4.1 was used for the discrete-time survival 
analysis. To facilitate clinical interpretation, results were also expressed as the number 
needed to be exposed (NNE), which has a similar definition to the popular summary statistic 
number needed to treat (NNT). In cohort studies, Bender & Blettner (2002) argue that the 
NNE is a preferable term when the considered agent is exposure rather than treatment19. In 
this study, the NNE is the average number of unexposed persons, i.e. women in the 
autologous oocyte group, needed to be exposed to donor oocytes, to observe one additional 
live birth19. The NNEs for all age groups were calculated from the adjusted odds ratios (AOR) 
and the CLBR for women in the autologous oocyte group, by means of the Bender & Blettner 
(2002) multiple logistic regression model19.  
Ethics 
Ethics approval for this study was granted by the Human Research Ethics Committee of 
University of Technology Sydney, Australia (UTS HREC REF NO. ETH16-0800). Access to the 
VARTA data was granted by VARTA. 
Results 
Table I presents the characteristics of the study population. The majority of women in the 
autologous group were aged 40 – 44 years (93%) with very few (7%) women aged ≥45 years. 
In contrast, in the donor oocyte group, 62% of women were aged 40-44 years and 38% aged 
 
 
≥45 years. The mean age of the oocyte donors was 33.7 years (range 21 to 45 years) with 49% 
aged 35 years and over. The rate of ICSI as the method of fertilisation was high in both groups 
(76% in autologous and 92.5% in the donor oocyte group). 
<Insert Table I here> 
Table II shows the number of embryos and the stage of the embryos at embryo transfer. The 
proportion of single and double blastocyst transfer was higher in the donor oocyte group than 
in the autologous group (49% versus 35% and 36% versus 24% respectively). Triple embryo 
transfer only occurred in the autologous group, with the majority of transfers at the cleavage 
stage (93%).  
<Insert Table II here> 
Table III displays the mean number of oocytes collected and the mean number of embryos 
suitable for transfer for freezing, per age group, in both the donor and autologous groups. 
<Insert Table III here> 
Table IV displays the CLBR by age for the donor and autologous groups. In the donor group, 
the CLBR ranged from 28.6%(for women aged 40 years) to 42.5% (for women aged 44 years) 
and in the autologous group it ranged from 1.4% (for women aged 45 years) to 12.5% (for 
women aged 40 years).  The discrete-time survival analysis with odds ratio (OR) and the 
associated 95% CI demonstrated that the donor oocyte group has a significantly higher CLBR 
than the autologous group across all ages.  At ages 44, 45 and ≥46 women in the donor 
oocyte group were at least ten times more likely to have a live birth than women in the 
autologous group. Overall the likelihood of a live birth was five times greater in the donor 
oocyte group than the autologous group, or if expressed as an NNE result, on average six 
 
 
women in the autologous oocyte group would need to receive donor oocytes to have one 
additional live birth.  
<Insert Table IV here> 
As shown in Table V, regardless of the recipient’s age, women with donors aged ≥40 years 
had a significantly lower CLBR when compared to recipients with younger donors. The highest 
overall CLBR (42.5%) was seen in women with donors <35 years.  
<Insert Table V here> 
Over six transfers, the CLBR was consistently higher in the donor oocyte group than the 
autologous group.  The increment in live births between cycle 2 and cycle 3 was 0.5% in the 
autologous and 3.3% in the donor oocyte group. The cycle specific and cumulative live birth 
rates (all ages) are presented in Table VI. 
<Insert Table VI here> 
Discussion 
This population-based cohort study shows that most women in their forties who access ART 
use their own oocytes despite the minimal chance of having a baby as a result. Unsurprisingly, 
we found that, across all age groups, women using donor oocytes were five times more likely 
to have a live birth than women using autologous oocytes. We found however that recipients 
with donors aged 40 years or older had a significantly lower CLBR, regardless of the recipient’s 
age. This confirms that the age of the oocytes is critical for the chance of success and lends 
support to the requirement for an upper age limit for oocyte donors20. In spite of the known 
low chance of success, the overwhelming majority of women used their own oocytes, likely 
reflecting people’s preference for biologically related children, societal expectations of family 
 
 
formation, the regulatory environment which only allows altruistic donation, a lack of donor 
oocytes, and funding arrangements for ART in Australia which do not impose age limits on 
women who wish to use their own oocytes. 
The cost of ART has far-reaching implications on access and uptake of fertility treatment21. 
Australia is considered to have one of the most supportive funding arrangements for ART 
globally. Medicare, the Australian Government’s universal health insurance scheme 
reimburses up to the 80% of costs incurred for ART, once a certain threshold has been 
reached, irrespective of the woman’s age21. The few available studies on access to ART 
suggest that affordability is a powerful determinant of whether couples pursue treatment21,22.  
In Australia, the demand for donated oocytes exceeds supply23, which may partly explain the 
high proportion of women in this study using their own oocytes in ART. Australian regulation 
only permits altruistic gamete and embryo donation24,25. Typically in Australia, women who 
need donor oocytes have to join long waiting lists due to a scarcity of donors, or access 
donated oocytes from clinics abroad such as The World Egg Bank which comply with 
Australian national regulation and state laws. However, most recipient couples rely on a 
friend or a relative to donate oocytes or find a donor through an online forum11. It has been 
suggested that oocyte donors should be compensated for the inconvenience and risk 
associated with donation, and this may increase the supply of donated oocytes in Australia. 
The Australian Human Ethics Committee, through public consultation, explored attitudes 
relating to compensation for egg donors during 2014 and 2015. A key question still under 
consideration is how much Australian oocyte donors should be compensated to make it 
worthwhile for them without being too high and potentially causing poor women to donate 
for financial reasons24. 
 
 
The desire to have a biologically related child may also be a reason why so many of the women 
in our study used their own oocytes.  A number of studies show that both women and men 
over-estimate the ability of ART to compensate for any age-related fertility decline and 
believe that up until menopause, ART can assist most women to have a child using their own 
eggs5,8,20,26. The results of the current study highlight the need for fertility health promotion 
initiatives to improve awareness about the impact of age on fertility and the chance of 
spontaneous and ART conception. Hammarberg and colleagues argue that fertility health 
promotion in schools and primary care encounters can improve young people's 
understanding of the limitations of fertility and may lead to more people planning to have 
children during their most fertile years27. Furthermore, more awareness of the limitations of 
ART is needed to counteract media reports of celebrities having babies in their late 40’s which 
can lead to the erroneous belief that ART can overcome age-related fertility decline28.  
Limitations 
A limitation of this study was the disparity between the number of women in the donor group 
compared to the autologous group. In Australia and New Zealand, only altruistic gamete and 
embryo donation is permissible which contributes to the current shortage of oocyte donors. 
In addition, a small proportion of women (less than 2%), were counted in both the donor and 
autologous groups as they were treated with autologous oocytes before being treated with 
donor oocytes. While judged as unlikely due to the small numbers, this may have influenced 
the study findings. The lack of information available on clinic-specific protocols and processes 
for ART (such as the assessment of oocyte quality and ICSI timing) as these may potentially 
have an impact on clinical outcomes29. Further studies are required to evaluate the influence 
of these kinds of technical aspects on clinical outcomes. Demographic confounders, including 
 
 
obesity and cigarette smoking, medical conditions and other residual confounders, which may 
have affected the findings of this study, are not recorded in the VARTA dataset.  
In conclusion, this study shows that most women in their forties who access ART use their 
own oocytes despite the minimal chance of success. We found that, across all age groups, 
women ≥40 years using donor oocytes were five times more likely to have a live birth than 
women using autologous oocytes. These findings can be used when counselling women ≥40 
years who contemplate using ART to conceive and help them make informed decisions about 
ART and whether to use their own or donor oocytes.  The most important part of counselling 
is to inform women that the donor should ideally be <40 years or for an even better chance 
of success, younger than 35 years. The findings can also inform government policies and 
health promotion campaigns encouraging childbearing when the chance of spontaneous 
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